The Paradox Role of Regulatory T Cells in Ischemic Stroke

Table 1

Outcome of current studies in murine model.

Study (year)	Outcome	Infarct volume	Treg depletion	Treg adoption	Major findings
Liesz et al. (2009) [55]	Protective	<30 mm^3	Anti-CD25 mAb	None	Larger infarcts and worse neurological function in depletion group on day 7, but not day 1 or 3
			None	Total CD4+ T cells, Tregs or CD4+CD25− T cells to RAG2^−/− mice; 8∗10^6/mouse; 7 days before MCAO	Larger infarcts in CD4+CD25− group on day 7
Ren et al. (2011) [60]	Neutral	~50 mm^3	DEREG mouse; (DT before MCAO)	None	No significant difference associated with depletion within 4 days after MCAO
Li et al. (2012) [51]	Protective	20–60 mm^3	None	Tregs to wide type; 2∗10^6/mouse; the 2nd, 6th, and 24th hours after reperfusion	Reduced infarcts and better neurological function in adoption group out to day 28
			Anti-CD25 mAb	Tregs to wide type; 2∗10^6/mouse; the 2nd, 6th and 24th hours after reperfusion
Stubbe et al. (2013) [52]	Neutral	~40 mm^3	Anti-CD25 mAb	None	No significant difference associated with depletion
Kleinschnitz et al. (2013) [50]	Deleterious	60–90 mm^3	DEREG mouse; (DT before MCAO)		Smaller infarcts and better neurological function in depletion group on days 1 and 4; no secondary infarct growth associated with depletion by day 7
		5–10 mm^3	DEREG mouse; (DT after MCAO)		No secondary infarct growth associated with depletion by day 7
		5–10 mm^3	DEREG mouse; (DT before MCAO)	CD4+CD25+Tregs or CD4+CD25− T cells or CD4+CD25+FoxP3+ Tregs or CD4+CD25− FoxP3− T cells to RAG2^−/− mice; 7.5∗10^5/mouse; 1 day before MCAO	Larger infarcts in all 4 adoption groups than Rag^−/− group; no difference between any adoption group and Rag^+/+ group
Gu et al. (2012) [61]	Neutral			Ebi3 KO	No significant difference associated with depletion within 2 days after MCAO